08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors
04/07/2025 – AB Science today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease
30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt
23/06/2025 – AB Science today announced that a new study from an independent research team based in China presents new evidences showing that masitinib offers a promising new approach to treating Alzheimer’s disease
12/06/2025 – AB Science today announced that the patent office of Canada has granted a patent protecting the composition of matter of AB8939, and closely related compounds, until 2036
09/06/2025 – AB Science today announced that the European Medicine Agency (EMA) has approved the extension of the shelf life of its veterinary medicine MASIVET® from 36 months to 48 months
23/05/2025 – AB Science today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors
20/05/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors
19/05/2025 – AB Science today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 infection causing COVID-19
15/05/2025 – AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib